Abstracts Archive - Page 1225 of 2607 - ACR Meeting Abstracts

Abstract Number: 580 • 2018 ACR/ARHP Annual Meeting
Clinical Effectiveness of Tofacitinib 11mg Once Daily (QD) Versus Tofacitinib 5mg Twice Daily (BID) in the Corrona US RA Registry
Stanley Cohen¹, Heather J Litman², Connie Chen³, Tatjana Lukic³, Ann Madsen³, Liza Takiya⁴, Kimberly J Dandreo², Taylor Blachley² and Jeffrey Greenberg², ¹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ²Corrona LLC, Waltham, MA, ³Pfizer Inc, New York, NY, ⁴Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA, originally approved at 5 mg twice daily (BID). In 2016, an extended-release…
Abstract Number: 581 • 2018 ACR/ARHP Annual Meeting
Comparative Analysis of Outcomes Among Patients with Rheumatoid Arthritis Initiating Tofacitinib in Combination with Oral MTX Who Discontinue, Interrupt, or Persist with MTX
Stanley Cohen¹, Boulos Haraoui², Jeffrey R. Curtis³, Timothy Smith⁴, John Woolcott⁵, David Gruben⁶, Christopher W Murray⁵, Noriko Iikuni⁴, Andrew Koenig⁵ and James Harnett⁴, ¹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ²Institut de Rhumatologie de Montreal, Montreal, QC, Canada, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Pfizer Inc, New York, NY, ⁵Pfizer Inc, Collegeville, PA, ⁶Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA, in combination with MTX or other non‑biologic (nb)DMARDs, or as monotherapy. Two…
Abstract Number: 582 • 2018 ACR/ARHP Annual Meeting
Baseline Power Doppler and Multi-Biomarker Disease Activity Score Predict 12-Week Disease Activity Response to Tofacitinib
Amir Razmjou¹, Jenny Brook², Gurjit Kaeley³, David Elashoff² and Veena K. Ranganath⁴, ¹Internal Medicine, UCLA-David Geffen School of Medicine, Los Angeles, CA, ²Department of Medicine Statistics Core, UCLA David Geffen School of Medicine, Los Angeles, CA, ³UF Health Jacksonville, Jacksonville, FL, ⁴1000 VETERAN BLVD., RM 32-59, UCLA, Los Angeles, CA
Background/Purpose: Point of care tailored treatment strategies are of value to improve rheumatoid arthritis (RA) patient outcomes. Musculoskeletal ultrasound (MSUS) is increasingly used as a…
Abstract Number: 583 • 2018 ACR/ARHP Annual Meeting
Identification of a Protein Profile Useful to Predict Response to Methotrexate in Early Rheumatoid Arthritis Patients
Cristina Ruiz-Romero¹, Florencia Picchi², Lucia González², Rebecca Hands³, Valentina Calamia², Patricia Fernández⁴, Maria Camacho², Rocío Paz², Conrad Bessant⁵, Costantino Pitzalis³ and Francisco J Blanco⁶, ¹Rheumatology Division, ProteoRed, PRB2-ISCIII. INIBIC-Hospital Universitario A Coruña, A Coruña, Spain, ²Rheumatology Research Group, Proteomics Unit-ProteoRed/ISCIII, INIBIC-CHUAC, A Coruña, Spain, ³Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and The London, School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom, ⁴Proteomics group, Rheumatology Division, ProteoRed, PRB2-ISCIII. INIBIC-Hospital Universitario A Coruña, La Coruña, Spain, ⁵School of Biological and Chemical Sciences, Queen Mary University of London, London, United Kingdom, ⁶Rheumatology Divison, INIBIC-Hospital Universitario A Coruña, A Coruña, Spain
Background/Purpose: Among the best known disease-modifying antirheumatic drugs, Methotrexate (MTX) is one of the most effective and widely used medications. It is used as a…
Abstract Number: 584 • 2018 ACR/ARHP Annual Meeting
Changes in CD4+ T and B Cell Profile As Indicator of Clinical Remission to TNF Inhibitors in Patients with Rheumatoid Arthritis
Borja Hernández-Breijo^1,2, Israel Gañán-Nieto³, Cristina Sobrino³, Victoria Navarro-Compán¹, Ana Martínez^1,2, Carlota García-Hoz³, Javier Bachiller³, María Gema Bonilla Hernán^1,4, Garbiñe Roy⁵, Mónica Vázquez³, Alejandro Balsa^1,6, Luisa María Villar³, Dora Pascual-Salcedo¹, Eulalia Rodríguez-Martín³ and Chamaida Plasencia^1,4, ¹Immuno-Rheumatology research group, IdiPaz. La Paz University Hospital, Madrid, Spain, ²Immunology. La Paz University Hospital, Madrid, Spain, ³Immuno-Rheumatology research group, IRYCIS. Ramón y Cajal University Hospital, Madrid, Spain, ⁴Rheumatology, La Paz University Hospital, Madrid, Spain, ⁵Immunology. Ramón y Cajal University Hospital and IRYCIS, Madrid, Spain, ⁶Hospital Universitario La Paz, Madrid, Spain
Background/Purpose: TNF inhibitors (TNFi) are widely used for the treatment of rheumatoid arthritis (RA). This study aims to analyse the profile of peripheral blood mononuclear…
Abstract Number: 585 • 2018 ACR/ARHP Annual Meeting
The Role of Genetic Polymorphisms on the Response to Methotrexate Variations Among Rheumatoid Arthritis Patients in Saudi Arabia
Suzan Attar¹, Magdah Hagrass², Adel Abuzenadah³, Omar Fath Aldin¹, Rahaf Attar⁴, Rajaa Al-Raddadi⁵, Mansour Sulaiman² and Ahmed Aseri², ¹Internal Medicine, Department of Internal Medicine, King Abdulaziz University, Jeddah, Saudi Arabia, ²Pharmacology, Department of Pharmacology, King Abdulaziz University, Jeddah, Saudi Arabia, ³medical technology, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia, ⁴internal medicine, Department of Internal Medicine, King Abdulaziz University, Jeddah, Saudi Arabia, ⁵Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia
Background/Purpose: Low dose methotrexate (MTX) is one of the most commonly used disease-modifying anti-rheumatic drug for rheumatoid arthritis (RA) with excellent efficacy and safety profile. However, it…
Abstract Number: 586 • 2018 ACR/ARHP Annual Meeting
Effectiveness, Tolerability, and Safety of Tofacitinib in Rheumatoid Arthritis: A Retrospective Analysis of Real-World DATA from the ST. Gallen and-Aarau RA-Cohort
Ruediger Mueller¹, Caroline Hasler², Florian Popp³, Frederik Mattow⁴, Mirsada Durmisi⁵, Andrea Rubbert-Roth⁶, Alexander Souza⁷, Nicole Graf⁸, Hendrik Schulze-Koops⁹, Paul Hasler¹⁰ and Johannes von Kempis¹¹, ¹Division of Rheumatology, Kantonsspital St Gallen, St. Gallen, Switzerland, ²on of Rheumatology, Kantonsspital Aarau, Aarau, Switzerland, ³Division of Rheumatology, Immunology and Rehabilitation, Kantonsspital St. Gallen, St. Gallen, Switzerland, ⁴Kantonsspital St. Gallen, St. Gallen, Switzerland, ⁵Division of Rheumatology, Kantonsspital Aarau, Aarau, Switzerland, ⁶Kantonsspital St Gallen, St Gallen, Switzerland, ⁷Iterata AG, Gränichen, Switzerland, ⁸Graf Biostatistics, Winterthur, Switzerland, ⁹Ludwig-Maximilians-University, Munich, Germany, Munich, Germany, ¹⁰Kantonsspital Aarau AG, Aarau, Switzerland, ¹¹Division of Rheumatology and Immunology, Kantonsspital St. Gallen, St. Gallen, Switzerland
Background/Purpose: Tofacitinib is an oral JAK inhibitor approved for the treatment of RA. Efficacy and safety of tofacitinib have been shown in several randomized clinical…
Abstract Number: 587 • 2018 ACR/ARHP Annual Meeting
The Superiority of a Treat to Target Strategy over Conventional Treatment with Fixed Csdmard and Corticosteroids: A Multi-Centre Randomized Controlled Trial in RA Patients with Inadequate Response to Conventional Synthetic Dmards, and a New Therapy with Certolizumab Pegol
Ruediger Mueller¹, Michael Spaeth², Cord von Restorff³, Christoph Ackermann⁴ and Johannes von Kempis⁵, ¹Division of Rheumatology, Kantonsspital St Gallen, St. Gallen, Switzerland, ²Division of Rheumatology, Spital Linth, Uznach, Switzerland, ³Private rheumatologic practice, Männedorf, Switzerland, ⁴Private rheumatologic practice, Triesen, Liechtenstein, ⁵Division of Rheumatology and Immunology, Kantonsspital St. Gallen, St. Gallen, Switzerland
The superiority of a treat to target strategy over conventional treatment with fixed csDMARD and corticosteroids: a multi-centre randomized controlled trial in RA patients with…
Abstract Number: 588 • 2018 ACR/ARHP Annual Meeting
Acr Hybrid Analysis: Blinded Data from the Ongoing Phase IIb Trial with the EP4 Receptor Antagonist CR6086 in DMARD-Naïve Patients with Early Rheumatoid Arthritis
Cristina Vitalini, Beatrice Barbetta, Giampaolo Giacovelli, Nadia Brambilla, Massimo D'Amato, Federica Girolami and Lucio C. Rovati, Clinical Research Department, Rottapharm Biotech, Monza, Italy
Background/Purpose: The ACR Hybrid, officially recommended by the ACR as a revision to the ACR20/50/70 response criteria, combines the ACR20/50/70 scores with the mean percent…
Abstract Number: 589 • 2018 ACR/ARHP Annual Meeting
DAS28-CRP Versus DAS28-ESR and Thresholds for Disease Activity Category: Blinded Data from the Ongoing Phase IIb Trial with the EP4 Receptor Antagonist CR6086 in DMARD-Naïve Patients with Early Rheumatoid Arthritis
Cristina Vitalini, Beatrice Barbetta, Giampaolo Giacovelli, Nadia Brambilla, Massimo D'Amato, Federica Girolami and Lucio C. Rovati, Clinical Research Department, Rottapharm Biotech, Monza, Italy
Background/Purpose: In most patients with rheumatoid arthritis (RA) the 28-Joint Disease Activity Score (DAS28) values calculated using C-reactive protein (CRP) are lower than those calculated…
Abstract Number: 590 • 2018 ACR/ARHP Annual Meeting
Advances in Therapeutic Management with First Biological Therapy in Rheumatoid Arthritis throughout 15 Years
Patricia Bogas¹, Chamaida Plasencia², Victoria Navarro-Compán³, Diego Benavent², Gabriela Gonzalez², María Gema Bonilla Hernán², Irene Monjo¹ and Juan Molina¹, ¹Rheumatology, Rheumatology, La Paz University Hospital, Madrid, Spain, ²Rheumatology, La Paz University Hospital, Madrid, Spain, ³Immuno-Rheumatology research group, IdiPaz. La Paz University Hospital, Madrid, Spain
Background/Purpose: In the last two decades the treatment in patients with rheumatoid arthritis (RA) has undergone major advances, especially due to the appearance of new…
Abstract Number: 591 • 2018 ACR/ARHP Annual Meeting
Evaluation of MRI Ramris Score and Clinical Response in Patients with ACPA Positive Undifferentiated Arthritis Treated with Infliximab Versus Placebo
Thomas Kirchgesner¹, Bruno Vande Berg¹, Tatiana Sokolova², Laurent Meric de Bellefon², Adrien Nzeusseu Toukap³, Maria Stoenoiu⁴ and Patrick Durez², ¹Musculoskeletal Imaging Unit, Musculoskeletal Imaging Unit - Cliniques universitaires Saint-Luc - Université Catholique de Louvain - Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium, ²Rheumatology, Rheumatology - Cliniques universitaires Saint-Luc - Université Catholique de Louvain - Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium, ³Department of Rheumatology, Rheumatology - Cliniques universitaires Saint-Luc - Université Catholique de Louvain - Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium, ⁴Rheumatology department, Rheumatology - Cliniques universitaires Saint-Luc - Université Catholique de Louvain - Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium
Background/Purpose: Patients (Pts) with Undifferentiated Arthritis (UA), positive for ACPA antibodies are at high risk of progressing to Rheumatoid Arthritis (RA). TNF play a key…
Abstract Number: 592 • 2018 ACR/ARHP Annual Meeting
Improved Response to Etanercept Is Associated with Serum Vitamin D Levels in Rheumatoid Arthritis
W Dankers¹, Pascal HP de Jong², S Heil³, S van den Berg³, A Weel⁴, JMW Hazes⁵, E Colin⁶ and Erik Lubberts⁷, ¹Immunology, Erasmus MC, University Medical Center, Rotterdam, Netherlands, ²Rheumatology, Maasstad Hospital, Rotterdam, Netherlands, ³Clinincal Chemistry, Erasmus MC, Rotterdam, Netherlands, ⁴Rheumatology, Erasmus MC, Rotterdam, Netherlands, ⁵Department of Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, ⁶ZGT Almelo, Deventer, Netherlands, ⁷Erasmus Medical Center, Rheumatology, Rotterdam, Netherlands
Background/Purpose: Although treatment of rheumatoid arthritis (RA) has significantly improved during the past decades, many patients do not adequately respond or become resistant to current…
Abstract Number: 593 • 2018 ACR/ARHP Annual Meeting
Predictors of Persistence of Biologic Drug Step-Down Strategies in Inflammatory Arthritis: An Observational Study in Clinical Practice up to Seven Years of Follow-up
Sebastian C Rodriguez-Garcia¹, Raul Castellanos-Moreira Sr.¹, José Inciarte-Mundo², M. Victoria Hernández³, Virginia Ruiz-Esquide², Andrea Cuervo¹, Julio Ramírez², Juan Cañete¹, Jose Gomez Puerta¹ and Raimon Sanmartí¹, ¹Rheumatology Service, Hospital Clínic de Barcelona, Barcelona, Spain, ²Rheumatology, Hospital Clínic de Barcelona, Barcelona, Spain, ³Rheumatology, Hospital Clinic. Barcelona. Spain, Barcelona, Spain
Background/Purpose: Recommendations and guidelines for the management of Rheumatoid Arthritis (RA) and spondyloarthritis (SpA) with bDMARD include dose-tapering as an adequate option for patients on…
Abstract Number: 594 • 2018 ACR/ARHP Annual Meeting
Identification of Tocilizumab Treated RA Patients, Whom Are Not Likely to Show Long-Term Clinical Benefit; Reanalysis of the Biomarker Sub-Study of LITHE
Anne C. Bay-Jensen¹, Christian S. Thudium¹, Claus Christiansen² and Morten A. Karsdal¹, ¹Nordic Bioscience, Herlev, Denmark, ²Nordic Bioscience, Clinical Development, Herlev, Denmark
Background/Purpose: Tocilizumab, anti-interleukin 6 receptor (IL-6R) therapy, is an effective treatment of rheumatoid arthritis (RA). However, a significant amount of patients do not respond adequately…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].